Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China

Figure 2 The prevalence of metabolic dysfunction-associated fatty liver disease in a large-scale, longitudinal population-based cohort. A: Distribution of alanine aminotransferase (ALT) levels in participants with metabolic dysfunction-associated fatty liver disease (MAFLD); B: Differential analysis of ALT levels between healthy participants and those with MAFLD. The prevalence of MAFLD was 34.27%, and 83.13% of participants with MAFLD had normal ALT levels. ALT levels were significantly greater in MAFLD patients than in healthy individuals. ALT: Alanine aminotransferase; MAFLD: Metabolic dysfunction-associated fatty liver disease.